Pfizer (PFE.US) has announced that Jeffrey Legos, MD, will be joining the company and taking on the role of chief tumor officer.

On February 5, Pfizer (PFE.US) announced that Jeffrey Legos, MD, will join the company and serve as its Chief Tumor Officer, leading the company's oncology development efforts and overseeing all functions from preclinical through late-stage clinical development. Dr. Legos will report to Chris Boshoff, PhD, Pfizer's Chief Scientific Officer and Head of R&D, and will represent the Oncology Department in the Pfizer R&D leadership team. Dr. Legos will succeed Roger Dansey, who will transition to retirement as previously announced. Legos, MD, brings over two decades of successful leadership experience in managing large multinational teams across all functions and stages of oncology drug development, having secured over 40 global regulatory approvals for pharmaceuticals and companion diagnostics, including new molecular entities, product pipeline expansions, and pre-market approvals for devices. Prior to joining Pfizer, Legos, MD, served as Executive Vice President and Global Head of Oncology and Hematology Development at Novartis.